These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20089875)

  • 1. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.
    Yang H; Jager MJ; Grossniklaus HE
    Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):2835-42. PubMed ID: 20089875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.
    Sharma RK; Balaiya S; Chalam KV
    Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6906; author reply 6906-7. PubMed ID: 21123801
    [No Abstract]   [Full Text] [Related]  

  • 3. Low dose adjuvant angiostatin decreases hepatic micrometastasis in murine ocular melanoma model.
    Yang H; Akor C; Dithmar S; Grossniklaus HE
    Mol Vis; 2004 Dec; 10():987-95. PubMed ID: 15623988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab and intraocular tumors: an intriguing paradox.
    el Filali M; Ly LV; Luyten GP; Versluis M; Grossniklaus HE; van der Velden PA; Jager MJ
    Mol Vis; 2012; 18():2454-67. PubMed ID: 23077404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vivo xenograft murine human uveal melanoma model develops hepatic micrometastases.
    Yang H; Fang G; Huang X; Yu J; Hsieh CL; Grossniklaus HE
    Melanoma Res; 2008 Apr; 18(2):95-103. PubMed ID: 18337645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells.
    Yang H; Dithmar S; Grossniklaus HE
    Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2056-64. PubMed ID: 15223777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of IL-8 induced angiogenesis in uveal melanoma.
    Lattanzio L; Tonissi F; Torta I; Gianello L; Russi E; Milano G; Merlano M; Lo Nigro C
    Invest New Drugs; 2013 Oct; 31(5):1107-14. PubMed ID: 23912257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
    Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
    Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.
    Sudaka A; Susini A; Lo Nigro C; Fischel JL; Toussan N; Formento P; Tonissi F; Lattanzio L; Russi E; Etienne-Grimaldi MC; Merlano M; Milano G
    Invest New Drugs; 2013 Feb; 31(1):59-65. PubMed ID: 22714791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined immunologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model.
    Yang H; Grossniklaus HE
    Curr Eye Res; 2006 Jun; 31(6):557-62. PubMed ID: 16769615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF) to pigment epithelium derived factor (PEDF) RNA ratio in vitro and in a murine ocular melanoma model.
    Yang H; Xu Z; Iuvone PM; Grossniklaus HE
    Mol Vis; 2006 May; 12():511-7. PubMed ID: 16735992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma.
    Crosby MB; Yang H; Gao W; Zhang L; Grossniklaus HE
    Br J Ophthalmol; 2011 Jan; 95(1):112-7. PubMed ID: 20819828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive overexpression of pigment epithelium-derived factor inhibition of ocular melanoma growth and metastasis.
    Yang H; Grossniklaus HE
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):28-34. PubMed ID: 19661223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.
    Han YS; Lee JE; Jung JW; Lee JS
    Graefes Arch Clin Exp Ophthalmol; 2009 Apr; 247(4):541-8. PubMed ID: 18953554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fucoidan Does Not Exert Anti-Tumorigenic Effects on Uveal Melanoma Cell Lines.
    Dithmer M; Kirsch AM; Richert E; Fuchs S; Wang F; Schmidt H; Coupland SE; Roider J; Klettner A
    Mar Drugs; 2017 Jun; 15(7):. PubMed ID: 28640204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab treatment of meningeal melanoma metastases.
    Simonsen TG; Gaustad JV; Rofstad EK
    J Transl Med; 2020 Jan; 18(1):13. PubMed ID: 31915016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
    Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
    J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma.
    Hu K; Babapoor-Farrokhran S; Rodrigues M; Deshpande M; Puchner B; Kashiwabuchi F; Hassan SJ; Asnaghi L; Handa JT; Merbs S; Eberhart CG; Semenza GL; Montaner S; Sodhi A
    Oncotarget; 2016 Feb; 7(7):7816-28. PubMed ID: 26761211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.